Clinical data | |
---|---|
Other names | Volitinib |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.238.920 |
Chemical and physical data | |
Formula | C17H15N9 |
Molar mass | 345.370 g·mol−1 |
3D model ( JSmol) | |
| |
|
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. [1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. [2] It has been given conditional approval for these indication in China. [3]
Clinical data | |
---|---|
Other names | Volitinib |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.238.920 |
Chemical and physical data | |
Formula | C17H15N9 |
Molar mass | 345.370 g·mol−1 |
3D model ( JSmol) | |
| |
|
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. [1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. [2] It has been given conditional approval for these indication in China. [3]